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ABSTRACT 
The HLA-DRB1 locus is strongly associated with rheumatoid arthritis (RA) susceptibility, whereupon 
citrullinated self-peptides bind to HLA-DR molecules bearing the shared epitope (SE) amino acid motif. 
However, the differing propensity for citrullinated/non-citrullinated self-peptides to bind given HLA-DR 
allomorphs remains unclear. Here, we used a fluorescence polarization assay to determine a hierarchy of 
binding affinities of 34 self-peptides implicated in RA against three HLA-DRB1 allomorphs (HLA-
DRB1*04:01/*04:04/*04:05) each possessing the SE motif. For all three HLA-DRB1 allomorphs, we 
observed a strong correlation between binding affinity and citrullination at P4 of the bound peptide ligand. A 
differing hierarchy of peptide-binding affinities across the three HLA-DRB1 allomorphs was attributable to 
the ȕ-chain polymorphisms that resided outside the SE motif and were consistent with sequences of 
naturally presented peptide ligands. Structural determination of eight HLA–DR4–self-epitope complexes 
revealed strict conformational convergence of the P4-Cit and surrounding HLA ȕ-chain residues. 
Polymorphic residues that form part of the P1 and P9 pockets of the HLA-DR molecules provided a 
structural basis for the preferential binding of the citrullinated self-peptides to the HLA-DR4 allomorphs. 
Collectively, we provide a molecular basis for the interplay between citrullination of self-antigens and HLA 
polymorphisms that shape peptide–HLA-DR4 binding affinities in RA. 
 
  
INTRODUCTION 
Rheumatoid arthritis (RA)5 is an autoimmune disease of the synovial joints. A characteristic of RA is the 
presence of anti-citrullinated protein antibodies (ACPA) in sera, for which ∼70% of all patients are 
seropositive (1). ACPA target proteins that have undergone citrullination, a post-translational modification 
(PTM) process driven by a family of enzymes known as peptidyl-arginine deiminases (PAD), convert 
arginine to citrulline (2–4). PAD type 2 (PAD-2) and PAD-4 expression is closely associated with synovial 
joint inflammation in RA patients (5). Citrullination creates neo-self-antigens, and given the high rate of 
ACPA in RA patients, these antigens are considered the prime generators of the autoimmune CD4+ T cell 
response in ACPA+ RA. Citrulline-specific, antigen-experienced CD4+ T cells are found in HLA-DR4 
(DRA1*01:01/HLA-DRB1*04:01) RA patients as well as in HLA-DR4 (DRA1*01:01/HLA-DRB1*04:01) 
transgenic mice primed with citrullinated self-antigens (6–11). Furthermore, citrulline-specific Th1 and 
Th17 cells are increased in the HLA-DRB1*04:01+ RA patients, and pro-inflammatory cytokines are 
produced by CD4+ T cells in response to citrullinated self-antigens (8–11). Sources for the primary RA-
associated autoantigens may be from the site of disease, including articular cartilage and synovial fluids (12–
14), but others may be derived from blood plasma or surrounding mucosal tissues that are susceptible to 
inflammation (2). These proteins could undergo PTMs during numerous physiologic processes, including 
infection, apoptosis, and cellular stress. Some of the best-characterized autoantigens that bind ACPAs are 
citrullinated vimentin, fibrinogen, α-enolase, and type II collagen, which are present at high levels in the 
joint synovium (3, 15). 
 
One of the key inherited risk factors that contribute to ACPA-positive RA is the human leukocyte antigen 
(HLA) class II loci, namely HLA-DRB1, which encodes the HLA class II antigen-presenting molecules (16–
21). The antigen-binding groove of the HLA class II molecule can accommodate peptide ligands that vary in 
length, but the main pockets that interact most strongly with the bound peptide are P1, P4, P6, P7, and P9, 
which can accommodate the side chains of the peptide residues 1, 4, 6, 7, and 9 (22, 23). A conserved amino 
acid sequence QKRAA, QRRAA, or RRRAA in position 70–74 of the HLA-DRB1 chain, known as the 
shared epitope (SE) motif, is highly prevalent (∼90%) among ACPA seropositive patients (11, 16). This SE 
motif defines the P4 pocket of the high-risk HLA-DRB1 RA-associated allomorphs. Subsequent genome-
wide association studies have shown that two polymorphisms encoding ȕ-chain residues at positions 11 and 
13 at the base of the P4 pocket are also strongly associated with RA susceptibility (16). We have previously 
reported the structural basis for the association of the SE, citrullination, and RA by showing the size and 
charge of the P4 pocket accommodate antigens with a citrulline residue in the P4 position but prevents the 
binding of peptide ligands with the natively-encoded positively-charged P4-Arg (24). 
 
Although citrullinated peptides have generally shown enhanced affinity to several SE HLA-DRB1 
allomorphs relative to native peptides (25), the affinity of individual peptides has not been compared, with 
respect to polymorphisms outside the SE motif. Here, we show the affinity of citrullinated peptides across 
three different HLA-DRB1 allomorphs and reveal the key interactions between RA-associated antigens with 
RA-susceptible HLA-SE allomorphs. The crystals structures of eight citrullinated peptides bound to HLA-
DRB1*04:01/*04:04/*04:05 demonstrate the close convergence of the binding modes of the P4-Cit, with 
polymorphisms outside this pocket accounting for the hierarchy of binding of citrullinated self-peptides to 
the three HLA-DR4 allomorphs. These specificities were also revealed in the natural repertoire of bound 
peptides, suggesting similar selective pressure operates on the self-peptide repertoire (immunopeptidome). 
Accordingly, we provide a molecular understanding of the interplay between the citrullination of self-
antigens and HLA polymorphism that shape peptide-HLA binding affinity in RA. 
 
 
Results 
P1 and P9 specificities distinguish the shared epitope-positive HLA-DR4 peptidomes 
The extent to which polymorphisms outside the P4 pocket contribute to the natural selection of peptides was 
established using monoallelic HLA-DR4+ antigen-presenting cells. For this purpose, we generated 
transfectants of the T2 cell line (class II-deficient) that expressed HLA-DM and either HLA DRB1*04:01, 
04:04, or 04:05. We have previously reported the immunopeptidomes of the HLA-DRB1*04:01+ and 
04:04+ cells (24). Each of these datasets contained over 1000–3000 unique and high confidence peptides, 
and although earlier reports have identified some HLA-DRB1*04:05 peptide ligands (26), here we report a 
large dataset of peptide ligands (n = 2935) from the same parental T2 cell line (Table S1). These endogenous 
peptide sequences determined from multiple peptide elution experiments were identified with high 
confidence using strict bioinformatic criteria that includes the removal of common contaminants (27). The 
motif for HLA-DRB1*04:05 generated using this approach (Fig. 1A) was in general agreement with 
previously determined motifs (28, 29) and, like the other SE+ DR4 allomorphs, disfavored Arg at P4 and 
showed strong preferences at P1 (Phe, Tyr, and Ile), P6 (Asp, Asn, and Thr), and P9 (Asp and Glu). To 
compare these preferences to the other SE+ HLA-DR4 allomorphs examined in this study, we generated a 
heat map of difference matrices to highlight differences in their naturally selected ligands (Fig. 1B). These 
heat maps show the difference in amino acid usage at each position of the core 9-mer of peptides bound to 
HLA-DRB1*04:05 compared with HLA-DRB1*04:01 or HLA-DRB1*04:04. Of note, HLA-DRB1*04:05 
selected peptides with similar P1 usage to HLA-DR*04:01 but a quite different selection of peptides with 
acidic P9 residues. In contrast, P1 and P9 differences were observed when HLA-DR*04:05-bound peptides 
were compared with HLA-DR*04:04-bound peptides, with an increase in aromatic amino acid selection at 
P1 and increased acidic residue selection at P9. 
 
 
RA autoantigen peptide affinity for HLA-DRB1 molecules 
Given the peptide preferences for the given HLA-DR4 allomorphs identified by mass spectrometry analyses, 
we next aimed to determine the propensity of self-antigens implicated in RA to bind to HLA-DRB1 
molecules possessing the SE motif. To establish this, we modified and undertook a fluorescence polarization 
assay across 34 peptides (Table 1 and Fig. 2) to measure the IC50 of each peptide bound to HLA-SE+ 
allomorphs, namely HLA-DRB1*04:01, HLA-DRB1*04:04, and HLA-DRB1*04:05. The HLA-
DRB1*04:04 molecule varies from HLA-DRB1*04:01 at two polymorphic positions, K71R and G86V, 
whereas HLA-DRB1*04:05 also differs from HLA-DRB1*04:01 at two positions, namely K71R and D57S 
within the antigen-binding cleft (Fig. 3A). The predicted core (P1–P9) registers for the HLA–peptide 
interaction are underlined in Table 1, generally with a hydrophobic P1-anchor residue and a P4-Arg or P4-
Cit. Arginine residues located outside the P4 pocket were also modified to citrulline and assayed for binding 
to the HLA-DRB1 allomorphs. The 34 peptides are predicted to place the citrulline in the P4 pocket, with 
the exception of the following: aggrecan-93Cit(89–103) and collagen type II-1240Cit(1237–1249) with a 
P2-Cit; histone-2B-73,80Cit(68–82) with a P3-Cit; and CILP-305Cit(297–309) with a P7-Cit. Four peptides 
possessed more than one citrullinated residue, namely aggrecan-93,95Cit(89–103), CILP-
988,991,994Cit(983–995), vimentin-64,69,71Cit(59–71), and fibrinogen ȕ-72,74Cit(69–81). 
 
Peptides with relative IC50 >β50 μM and <5 μM were considered non-binding and moderate binders to the 
HLA allomorphs, respectively. Peptides with relative IC50 <1 μM (Table 1) for the HLA allomorphs were 
considered to have high affinity. The fluorescence polarization values were converted to percentage of 
binding using the values for fully bound (∼150–250 mP) and free fluorescence (∼50 mP). Our aim was to 
determine the following: (a) whether the enhanced capacity of HLA-SE allomorphs to present self-antigens 
is restricted to P4-Cit or whether additional positions influence HLA binding; (b) whether a citrullinated 
epitope could bind to all HLA-SE with high affinity despite the polymorphisms in the peptide-binding cleft; 
and (c) whether there is a conserved structural basis for binding of citrullinated peptides to all three HLA 
allomorphs. 
 
 
P4-citrulline-enhanced peptide affinity for HLA-DRB1*SE allomorphs 
The binding affinity of aggrecan(89–103), vimentin(59–71), vimentin(66–78), vimentin(419–431), 
fibrinogen ȕ(69–81), LL37(47–59), LL37(62–74), and LL37(86–98) possessing P4-Cit was increased by at 
least 4-fold in comparison with P4-Arg in the native sequence when bound to HLA-DRB1*04:01 (Table 
1 and Fig. 2A). The P4-Cit peptide-mediated affinity enhancement for HLA-DRB1*04:01 was significant 
(p value < 0.05; one-way analysis of variance) in comparison with the P4-Arg counterpart or peptides with a 
single citrulline residue at the P2, P3, or P7 positions. The peptide affinity for native and citrullinated 
collagen type II(1237–1249) (Cit1240 in position P2) in HLA-DRB1*04:01 did not differ significantly, with 
relative IC50 values of 0.γ0 and 0.46 μM, respectively. The DRB1*04:01 peptide affinity for both native 
and citrullinated histone 2B(68–82) (Cit73 in position P3) were similar with relative IC50 values of 0.16 and 
0.β8 μM, and CILP(β97–309) (Cit305 in position P7) with relative IC50 values of 9.50 and 8.06 μM. These 
data indicate that citrullination outside the P4 pocket does not impact the peptide affinity for the given HLA 
allomorphs. 
 The overall affinity of the peptide for DRB1*04:01/*04:04/*04:05 was influenced by the P1-anchor residue 
in the peptide. For example, peptide antigens with a P1 residue such as Gly, Ile, and Leu in aggrecan(89–
103) (ATEGRVRVNSAYQDK), LL37(47–59) (DGINQRSSDANLY), and LL37(62–74) 
(LDLDPRPTMDGDP) showed lower affinity for HLA-DRB1*04:01 despite the presence of P4-Cit (Table 
1 and Fig. 2A). In contrast, HLA-DRB1*04:01 exhibited a higher affinity for aggrecan-93,95Cit(89–103) 
(G92Y) that possessed a Tyr instead of Gly in the P1 position. However, a P1-Tyr is disfavored in HLA-
DRB1*04:04 due to the presence of the G86V polymorphism near the P1 pocket (Fig. 3A). For example, 
HLA-DRB1*04:04 binds poorly to aggrecan-93,95Cit(89–103) (G92Y) (ATEYXVXVNSAYQDK), 
vimentin-64Cit(59–71) (GVYATXSSAVRLR), fibrinogen ȕ-74Cit(69-81) (GGYRAXPAKAAAT), and the 
reference peptide HA(306–318) (PKYVKQNTLKLAT) with a relative IC50 >8 μM. This observation is 
consistent with the previous finding that HLA-DRB1*04:04 did not bind to the immunodominant CII(259–
273) peptide, which is immunodominant in DRB1*0101 and *0401 mice with collagen-induced arthritis 
(30, 31). In the absence of a large P1-anchor, HLA-DRB1*04:05 binds with higher affinity (relative IC50 <1 
μM) to peptides that are predicted to possess a negatively-charged Glu or Asp in the P9 pocket, including 
CILP-305Cit(297–309) (ATIKAEFVRAETP) and vimentin-424Cit(419–431) (SSLNLXETNLDSL). HLA-
DRB1*04:05 also showed a similar affinity for native and citrullinated aggrecan(89–103), which suggests 
the peptide-binding register may have shifted to accommodate an aspartate residue within the P9 pocket. 
Like HLA-DRB1*04:04, HLA-DRB1*04:05 bound poorly to the CII(259–273) peptide. This is presumably 
due to the suboptimal nature of the P9-Gly residue, which is much less represented in the peptidome of 
HLA-DRB1*04:05 than the other two allomorphs (Fig. 1B) and is likely attributable to the D57S 
polymorphism (Fig. 3, D and E). Accordingly, although P4-Cit enhances binding to the HLA-DRB1 
allomorphs, peptide residues outside the P4 pocket impact on the peptide-binding affinity in a manner that is 
shaped by HLA polymorphism. 
 
 
Overlapping sequences of vimentin bind to HLA-SE allomorphs 
Citrullinated vimentin peptides stimulate a dose-dependent response in PBMCs from RA patients (6) as well 
as CD4+ T cells isolated from immunized HLA-DR4 transgenic mice (25). Here, we tested three regions of 
vimentin: positions 59–71 (GVYATRSSAVRLR), 66–78 (SAVRLRSSVPGVR), and 419–431 
(SSLNLXETNLDSL). HLA-DRB1*04:01 binds to vimentin-71Cit(66–78) with relatively high affinity 
(IC50 0.17 μM), compared with vimentin-64Cit(59–71) at 1.06 μM and vimentin-64,69,71Cit(59–71) at 
5.16 μM (Table 1, Fig. 2A). The HLA-DRB1*04:04 allomorph exhibited a preference for vimentin-
71Cit(66–78) (IC50 = 0.09 μM) in comparison with vimentin-64Cit(59–71) (IC50= 8.γ8 μM) and vimentin-
64,69,71Cit(59–71) (IC50 = 46.ββ μM) (Table 1 and Fig. 2B). In contrast, HLA-DRB1*04:05 had a strong 
preference for vimentin-424Cit(419–431) with a relative IC50 of 0.0γ μM compared with vimentin-
64Cit(59–71) and vimentin-71Cit(66–78), with IC50 values of β.04 and 1.91 μM, respectively (Table 
1 and Fig. 2C). These differing binding preferences suggest that the HLA-DR ȕ-chain polymorphism can 
impact antigen hierarchies in disease development. 
 
 
Increased citrullination of self-antigens do not improve binding affinity for HLA-SE 
Fibrinogen ȕ-72,74Cit(69–81) showed lower binding affinity for HLA-DRB1*04:01 and HLA-DRB1*04:05 
in comparison with fibrinogen ȕ-74Cit(69–81) (Table 1, Fig. 2, A and C). Similarly, CILP-
988,991,994Cit(983–995) binds with lower affinity compared with a single P4-Cit residue when bound to 
HLA-DRB1*04:05. Furthermore, HLA-DRB1*04:05 binds with slightly weaker affinity (IC50 of 1.0γ μM) 
to vimentin-64,69,71Cit(66–78) when compared with a single citrullinated residue at the P4 position. 
Although the aggrecan(89–103) peptide was a poor binder to the HLA-SE allomorphs, two citrulline 
residues at positions P2 and P4 (i.e. aggrecan-93Cit(89–103) or aggrecan-95Cit(89–103) versus aggrecan-
93,95Cit(89–103)) did not enhance peptide affinity. Accordingly, increased citrullination of self-antigens 
does not increase affinity for the HLA-DRB1 allomorphs. 
 
 
Structural comparison of HLA-DR4 with RA-associated autoantigens 
Next, we ascertained whether the presence of multiple citrullinated residues in a given epitope caused a 
register shift when bound to a given HLA-DRB1 allomorph and how the polymorphisms of the HLA-SE 
allomorphs impact peptide binding. To address this, we solved the crystal structures of HLA-DRB1*04:01 
with a collagen type II-1240Cit(1237–1249) (P2-Cit), fibrinogen ȕ-74Cit(69–81), and fibrinogen ȕ-
72,74Cit(69–81) (P2, P4-Cit); HLA-DRB1*04:01 and HLA-DRB1*04:04 with the same peptide LL37–
91Cit(86–98); HLA-DRB1*04:04 with both native and citrullinated histone2B(68–82); and HLA-
DRB1*04:05 with vimentin424Cit(419–431) (Tables 2 and 3). 
 
 
Conserved orientation of citrulline in the P4 pocket of HLA-SE 
The HLA-DRB1*04:01/*04:04/*04:05 allomorphs bind partially overlapping, but not identical, sets of 
peptides; thus the polymorphic residues must be involved in determining the varying binding specificities 
(Table 1 and Fig. 2). To explore the role of the polymorphic site, Lys-71ȕ/Arg-71ȕ, in the SE motif, we 
solved crystal structures of HLA-DRB1*04:01 and HLADRB1*04:04 in complex with the same peptide, 
LL37–91Cit(86–98) (Fig. 4, A and B). Superposition of these two structures revealed that they bind in a 
similar location and adopt a closely related conformation. The P4-Cit side chain of LL37–91Cit(86–98) bent 
upward and leaned against Phe-β6ȕ and Tyr-78ȕ in the P4 pocket of HLA-DRB1*04:01 and hydrogen 
bonded to Lys-71ȕ and Gln-70ȕ. The P4-Cit of LL37–91Cit(86–98) in HLA-DRB1*04:04 also packed 
against Phe-β6ȕ and Tyr-78ȕ and formed a hydrogen bond with Arg-71ȕ, the latter of which was stabilized 
by a hydrogen bond with Asp-β8ȕ and Tyr-47ȕ and P7-Gln in the peptide. The crystal structure of HLA-
DRB1*04:05 with vimentin-424Cit(419–431) also showed the P4-Cit adopted a conserved U-shaped 
upward conformation as seen in DRB1*04:01 and DRB1*0404 (Fig. 3C). Here, the P4-Cit of vimentin-
424Cit(419–431) hydrogen bonds with Arg-71ȕ, which was further stabilized by forming contacts with Asp-
β8ȕ, Tyr-47ȕ, and the P7-Gln. Overall, the P4-Cit is presented in a highly conserved manner in the three 
HLA-DRB1*04:01/*04:04/*04:05 allomorphs (Fig. 4I). 
 
Next, we asked whether having multiple citrullinated residues in a single epitope could cause a register shift 
when bound to a given HLA-DRB1 allomorph. To address this, we determined the structure of HLA-
DRB1*04:01 in complex with fibrinogen ȕ-74Cit(69–81) (IC50 = 0.58 μM), as well as fibrinogen ȕ-
72,74Cit(69–81) (IC50 = 0.90 μM) (Fig. 4, Dand E, and Tables 2 and 3). The P4-Cit of fibrinogen ȕ-
74Cit(69–81) and fibrinogen ȕ-72,74Cit(69–81) forms a direct hydrogen bond with Lys-71ȕ and a water-
mediated hydrogen bond with Thr-77ȕ in HLA-DRB1*04:01. The P2-Arg of fibrinogen ȕ-74Cit(69–81) 
pointed away from the peptide-binding groove and was freely accessible for TCR engagement. The P2-Cit 
of fibrinogen ȕ-72,74Cit(69–81) is also oriented away from the peptide-binding groove and hydrogen bonds 
to the carbonyl oxygen of Thr-77ȕ. Accordingly, no register shift in either citrullinated peptide was observed 
upon binding to HLA-DRB1*04:01. 
 
 
Citrulline in position P2 and P3 has minimal impact on peptide binding 
The presence of a citrulline in the P2 position does not affect peptide affinity for the HLA-SE tested (Table 
1 and Fig. 2). Indeed, the P2 pocket of the HLA-DRB1*04:01 could accommodate either arginine or 
citrulline as reflected in the fluorescence polarization data (Table 1 and Fig. 2). To address how an epitope 
with a P2-Cit could be accommodated, we determined the crystal structure of the HLA-DRB1*04:01 in 
complex with CII-1240Cit(1237–1249) that has a P2-Cit (Fig. 4F). The refined structure was very similar to 
that of HLA-DRB1*04:01 in complex with native CII(1237–1249) peptide (32). The bound CII peptide is 
extended across the peptide-binding site in a linear manner with Met-1239 occupying the P1 non-polar 
pocket, Asp-1242 in the P4 pocket, and Ala-1244 and Gly-1247 in the P6 and P9 pockets, respectively. The 
side chain of the P2-Cit in peptide CII-1240Cit(1237–1249), like the P2-Arg, projects away from the 
peptide-binding site of HLA-DRB1*04:01 and is freely accessible for TCR recognition. 
 
Next, we determined the structures of both native and citrullinated peptide histone2B(68–82) (P3-Cit) in 
complex with HLA-DRB1*04:04 (Fig. 4, G and H). These histone2B peptides bound to the HLA-
DRB1*04:04 with similar IC50 of 0.ββ and 0.β7 μM. The Pγ-Cit of the peptide histone2B-73,80Cit (68–82) 
hydrogen bonds with Asn-6βα in the HLA-DRB1*04:04, which is further stabilized by P6-SerO in the 
peptide that forms hydrogen bonds with Asn-6βα and His-1γȕ. The side chain of the Pγ-Arg is also solvent-
exposed in the HLA-DRB1*04:04-histone2B(68–82) complex, in which the guanidinium group hydrogen 
bonds to the carbonyl oxygen of the same Asn-6βα. 
Collectively, citrulline in position P2 or P3 in an epitope has minimal influence on peptide affinity for HLA-
SE as the side chains of these residues project outward from the peptide-binding groove, and thus both 
arginine and citrulline can be accommodated without changing the overall peptide affinity. 
Presentation of peptides with amino acid residues other than citrulline in the P4 pocket of HLA-SE 
The SE motif creates an electropositive P4 pocket encompassing a positively charged residue at position 
71ȕ. Consistent with our previous findings, these SE allomorphs allowed binding of autoantigen-derived 
peptides with polar or acidic residues at P4 but disallowed peptides with a P4 arginine due to electrostatic 
repulsion (24). In the HLA-DRB1*04:01–CII-1240Cit(1237–1249) complex, the side chain of the 
negatively charged P4-Asp, a preferred P4-anchor residue in the natural repertoire, is oriented upward 
similar to P4-Cit and forms a salt bridge with Lys-71ȕ in HLA-DRB1*04:01 (Fig. 4F). In the HLA-
DRB1*04:04 crystal structures in complex with either the native or citrullinated histone2B(68–82), Ile was 
placed in the P4 pocket of the HLA-DRB1*04:04 molecule. Subsequently, the Arg-71ȕ in the HLA-
DRB1*04:04 becomes available to form a salt bridge with Asp-β8ȕ and water-mediated hydrogen bond with 
the P7-Glu of the peptide (Fig. 4, G and H). Alignment of Cα backbone of the peptides bound to HLA-SE 
allomorphs highlights the conserved feature of citrulline and other non-positively charged residues. Thus, 
there is sufficient plasticity within the P4 pocket to accommodate differing amino acids. 
 
HLA polymorphism dictates peptide-binding affinity 
The crystal structures of the HLA-DR4–peptide complexes show that the peptides bind as a straight 
extended chain within the binding groove with no extensive conformational changes in the HLA-SE 
molecule itself. Three side chains of the self-peptides are accommodated by polymorphic P1, P4, and P9 
pockets in the HLA-DRB1*04:01/*04:04/*04:05-binding site. These pockets determine the peptide 
specificity of the HLA-DRB1*04:01/*04:04/*04:05. 
 
The fibrinogen ȕ-74Cit(69–81) (GGYRAXPAKAAAT) peptide provides an opportunity to examine the 
effect of polymorphism in the P1, P4, and P9 pockets on peptide binding affinity for each HLA-DR4 
allomorph. Fibrinogen ȕ(69–81) only binds to HLA-DRB1*04:01 and HLA-DRB1*04:05 when there is a 
P4-Cit (Table 1) suggesting that the Lys-71ȕ/Arg-71ȕ in the SE motif is the key discriminating factor 
preventing binding of the native peptide (Fig. 3C). However, the fibrinogen ȕ-74Cit(69–81) peptide did not 
bind to HLA-DRB1*04:04. HLA-DRB1*04:04 differs from 04:01 at two amino acids on the ȕ-chain: G86V 
and K71R that are located near the P1 and P4 pockets, respectively (Fig. 3A). Gly-86ȕ as visualized in the 
DRB1*04:01–fibrinogen ȕ-74Cit(69–81) complex (Figs. 3D and 4D) allows the binding of large aromatic 
and non-polar side chains such as Tyr. The substitution of Gly-86ȕ for Val-86ȕ places the Val side chain 
such that it would sterically hinder the binding of the P1-Tyr of this peptide to HLA-DRB1*04:04 (Fig. 3B). 
 
In contrast, HLA-DRB1*04:05 bound to the fibrinogen ȕ-74Cit(69–81) peptide but with lower affinity 
compared with HLA-DRB1*04:01. HLA-DRB1*04:05 differs from HLA-DRB1*04:01 and HLA-
DRB1*04:04 at two positions: D57S and G86V on the ȕ-chain, located near the P1 and P9 pockets, 
respectively. Arising from our immunopeptidome studies (Fig. 1), HLA-DRB1*04:05 has a very strong 
preference for peptides with Asp or Glu in the P9 position. Indeed, soluble recombinant HLA-DRB1*04:05 
was only expressed with a modified CLIP (as described under “Experimental procedures”) but not with the 
invariant CLIP in HEK293S cells. The Ser-57ȕ in the P9 pocket of HLA-DRB1*04:05, as observed in the 
structure of HLA-DRB1*04:05–vimentin-424Cit(419–431) complex, forms extensive contacts with the Asp 
in the P9 position of the peptide (Fig. 3, D and E). Therefore, the lower binding affinity of fibrinogen ȕ-
74Cit(69–81) to HLA-DRB1*04:05 compared with HLA-DRB1*04:01 is likely due to the unfavorable Ala 
at P9. This D57S variant in HLA-DRB1*04:05 may form a less stable complex with class II-associated 
invariant chain peptide compared with HLA-DRB1*04:01 and HLA-DRB1*04:04, which have Asp-57ȕ that 
normally forms a salt bridge with Arg-86α (33). Although there is a strong correlation between the ACPA 
titer in RA patient sera and the SE motif, the binding of citrullinated peptides is fine-tuned by distinct P1 and 
P9 specificities of the different SE + HLA-DR4 allomorphs. 
 
 
DISCUSSION 
Although HLA-DR4 molecules can present a range of citrullinated self-peptides that are associated with RA, 
the binding hierarchy of such peptides against a given HLA-SE molecule was unclear. A PTM peptide may 
generate a novel T cell epitope in two ways: (i) increased MHC class II binding affinity by modifying a key 
anchor residue, or (ii) modification of a non-anchor but solvent-exposed residue for TCR contact (34). A 
recent study on RA-associated HLA-DRB1*14:02 that encodes two polymorphic residues at the base of the 
P4 pocket (V11S and H13S) showed that, in contrast to DRB*04:01, both citrullinated and non-citrullinated 
peptides can be accommodated within the HLA-DRB1*14:02 molecule and stimulate a T cell response 
among Indigenous Native American RA patients (21). Here, we addressed the impact of HLA 
polymorphism and peptide citrullination on the HLA-SE binding hierarchy of self-peptides implicated in 
RA. 
 
The shared epitope residues are critical in selecting specific amino acids at position P4 of peptide that will 
bind to DR4 as reflected in the fluorescent polarization assay carried out across 34 RA-related self-peptides. 
In general, P4-Cit increased peptide affinity for the majority of the citrullinated peptides for HLA-
DRB1*04:01/*04:04/*04:05 and is accommodated in a highly conserved manner in the P4 pocket of the 
HLA-SE as shown in the series of crystal structures solved here and in earlier studies (11, 24). Our data also 
showed that not all HLA allomorphs bind to citrullinated antigens with the same affinity and that citrulline 
outside of the P4 pocket has minimal impact on the peptide-HLA affinity compared with their native 
arginine counterpart. 
 
The HLA-DRB1*04:01/*04:04/*04:05 bound to an overlapping but not an identical set of citrullinated 
peptides. This is most likely attributable to polymorphic residues within the peptide-binding cleft of these 
HLA-SE allomorphs and is also reflected in the selection of naturally presented peptides by these different 
HLA-DR4 allomorphs. Moreover, the majority of these self-antigens were identified in studies utilizing 
either HLA-DRB1*04:01 RA patients PBMC or DR4/IE transgenic mice (Table 1), which may explain why 
certain citrullinated self-peptides bound better to HLA-DRB1*04:01 but not HLA-DRB1*04:04/*04:05 
(35). Thus, there is a need for further epitope discovery in the context of these other HLA-DR4-SE 
allomorphs. It also appears that each HLA allomorph has its own binding hierarchy for these RA-associated 
T cell epitopes. Whether the hierarchy of peptides reflects the immunodominant epitopes responsible for RA 
disease development in patients carrying specific RA-susceptible alleles will depend on T cell studies in 
vivo and structural analysis with the TCR. There are some parallels with other autoimmune-like diseases, 
such as celiac disease, where PTM peptides could bind to HLA allomorphs with higher affinity and 
subsequently form more stable peptide–MHC complexes and prolong antigen presentation to the 
autoreactive T cells at the site of inflammation (36–39). Further studies aimed at determining whether a 
correlation between the rank order of RA-associated epitopes and disease pathogenesis exists will help to 
identify key autoantigens involved in RA development. 
 
 
EXPERIMENTAL PROCEDURES 
Peptides 
Panels of 13–15-mer peptides with overlapping sequences spanning sections of the vimentin, aggrecan, 
fibrinogen, cartilage-intermediate proteins (CILP), collagen type II, and LL37 were synthesized by GL 
Biochem (Shanghai, China). Arginine in the peptides was systematically replaced with citrulline where it 
was appropriate (Table 1). For competition binding assay, the N-terminally acetylated HA(306–318) analog 
Ac-PRFVK(Tamra)QNTLRLAT was labeled with TAMRA through the primary amine Lys-310 (GL 
Biochem, Shanghai, China). This peptide was shown to bind to HLA-DRB1* alleles in a fluorescent 
polarization assay (40). Lysine to arginine modification at positions 307 and 315 was made to the peptide to 
limit fluorescent labeling occurring at Lys-310 only. Each peptide was dissolved in water, TBS (10 
mM Tris-Cl, pH 8, 150 mM NaCl), or DMSO at 1 mM and subsequently diluted as needed. Peptide 
concentration was determined by 215 nM peptide carbon backbone measurements. 
 
Fluorescence polarization assay 
Various concentrations of each test peptide (range from 500 to 0 μM) were incubated in competition with 20 
nM fluorescent reference peptides to bind with 100 nMrecombinant HLA-DR protein in the presence of 20 
nM HLA-DM in Assay Buffer (100 mM trisodium citrate, pH 5.4, 50 mM NaCl, 5 mM EDTA), as 
described previously (40). Fluorescent polarization was measured after 24 or 72 h of incubation at 37 °C 
using PHERAstar microplate reader (BMG LABTECH). Peptide-binding curves were simulated by non-
linear regression with Prism software (Version 7.01, GraphPad Software Inc.) using a sigmoidal dose-
response curve. IC50 binding values were calculated as the peptide concentration needed for 50% inhibition 
of reference peptide binding. Relative binding values (%) were calculated as the IC50 value of the substituted 
peptide divided by the IC50 value of the non-substituted peptide at a given concentration (×100). 
 
Expression and purification of HLA-DR4 
The cDNA encoding extracellular domains of HLA-DRB1*04:01/-HLA-DRB1*04:02/-HLA-DRB1*04:05 
were separately cloned into the pHLsec expression vector with a sequence encoding an N-terminal 
covalently linked factor Xa-cleavable, Strep-tag MHC class II-associated invariant chain peptide (Strep-
CLIP; WSHPQFEKGAPVSKMRMATPLLMQA) (24). To express HLA-DRB1*04:05 recombinant 
protein, a methionine to aspartic acid (underlined; WSHPQFEKGAPVSKMRMATPLLDQA) was 
introduced to enhance CLIP affinity for HLA-DRB1*04:05 and subsequently heterodimer stability for 
expression and downstream purification. Soluble recombinant HLA-DRB1* proteins were expressed in 
HEK293S (GnTI−/−) cells (41) and purified with a three-step strategy using immobilized metal affinity 
(nickel-Sepharose 6 Fast Flow; GE Healthcare), size-exclusion (Superdex 200; GE Healthcare) and anion-
exchange (HitrapQ; GE Healthcare) chromatography as described previously (24). 
 
Peptide loading of HLA-DR4 
HLA-DRB1*-Strep-CLIP was incubated with factor Xa (New England Biolabs) in the presence of 2 
mM CaCl2 for 6 h at room temperature to remove the covalent linked Strep-CLIP peptide. This invariant 
peptide was exchanged with test peptides in solution at 20-fold molar excess, catalyzed by HLA-DM at 1:5 
DM/HLA-DRB1* ratio. The exchange was done between 24 and 72 h at 37 °C in 50 mM tri-sodium citrate, 
pH 5.4, and 5 mM EDTA. The peptide-loaded HLA-DRB1* was separated from unloaded HLA-DRB1*-
CLIP and HLA-DM using StrepTactin-Sepharose (IBA, Göttingen, Germany). The unbound fraction, 
containing HLA-DRB1* loaded with test peptides, was concentrated for structural studies. 
 
Protein crystallization and structural determination 
For crystallization, HLA-DRB1* was buffer-exchanged to 25 mM Tris, pH 7.6, 50 mMNaCl, and 2 
mM CaCl2. The Fos/Jun zippers were removed by an overnight incubation with enterokinase (New England 
Biolabs) at room temperature. Subsequently, the extracellular domain of the heterodimer HLA-DRB1* 
loaded with the peptide of interest was purified using anion-exchange chromatography (HitrapQ, GE 
Healthcare). HLA-DRB1* in complex with peptides was crystallized in the presence of 16–30% PEG3350, 
200 mM potassium nitrate, 100 mM Bistris propane, pH 7.6. Plate-like crystals were exposed to 
cryoprotectant, 16% ethylene glycol for 30 s before being flash-cooled in liquid nitrogen. A Morpheus 
crystallization condition (42) containing 100 mMimidazole/MES, pH 6.5, 20 mM NPS mix, 12.5% MPD, 8–
12% PEG3350, 12.5% PEG1000 were used for the HLA-DRB1*–peptide complex that did not crystallize in 
the previous condition described. Data sets were collected on the MX1 or MX2 beamline of the Australian 
Synchrotron. 
Data were integrated with XDS or iMOSFLM and scaled and merged in Aimless. Phases were obtained 
using molecular replacement in PhaserMR, CCP4 suite (43). The PDB entry 4MDI (chain A and B, without 
glycans or peptides) was used as search model for HLA-DRB1* for molecular replacement. The structures 
were built and refined in Coot and REFMAC/PHENIX (44). Final model was validated in Molprobity (45). 
 
Repertoire analysis of HLA-DR4 allomorphs 
T2-HLA-DRB1*04:05 cells expressing HLA-DM were generated via retroviral transduction of the parental 
T2 line as described previously (46). Cells were expanded in RPMI 1640 medium, 10% FCS and pellets of 
109 cells snap-frozen in liquid nitrogen. Cells were ground under cryogenic conditions and resuspended in 
lysis buffer (0.5% IGEPAL, 50 mM Tris, pH 8, 150 mM NaCl, and protease inhibitors) as described 
previously (47, 48). Cleared lysates were passed over a protein A pre-column followed by an affinity 
column cross-linked with a monoclonal antibody specific for HLA-DR (LB3.1). Peptide–MHC complexes 
were eluted from the column by acidification with 10% acetic acid. Peptides were isolated using reversed-
phase HPLC (Chromolith C18 Speed Rod, Merck) on an Akta Ettan HPLC system (GE Healthcare). 
Fractions were concentrated and run on an AB SCIEX 5600+ triple TOF high-resolution mass spectrometer 
as described (27). Acquired data were searched against the human proteome (Uniprot/SwissProt version 
2016_12) using ProteinPilotTM software version 5 (AB SCIEX). The resulting peptide identities were subject 
to strict bioinformatic criteria, including the use of a decoy database to calculate the false discovery rate 
(FDR). A 5% FDR cutoff was applied, and the filtered dataset was further analyzed manually to exclude 
redundant peptides and known contaminants. To generate motifs, the minimal core sequences found within 
nested sets were extracted, and the resulting list of peptides were aligned using MEME, where motif width 
was set to 9–15 and motif distribution set to “one per sequence” (49). Peptides derived from HLA or 
immunoglobulin molecules were not included in the final motif analysis. Motifs were submitted to iceLogo 
for visualization using the frequencies of amino acids in the human proteome as a reference set (50). 
Comparison was made to previously published HLA-DR*04:01 and 04:04 datasets using standard statistical 
tools (24). 
 
  
  
Abbreviations: 
RA  -  rheumatoid arthritis 
SE  -  shared epitope 
ACPA  -  anti-citrullinated protein antibody 
Bistris propane  -  1,3-bis[tris(hydroxymethyl)methylamino]propane 
PTM  -  post-translational modification 
PAD  -  peptidyl-arginine deiminase 
Cit  -  citrulline 
TCR  -  T cell response 
PBMC  -  peripheral blood mononuclear cell 
FDR  -  false discovery rate 
TAMRA  -  6-carboxy-N,N,N′,N′-tetramethylrhodamine. 
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Table 1 
IC50 values in (μM) candidate RA associated autoantigens bound to HLA-SE alleles: DRB1*04:01, 
DRB1*04:04 and DRB1*04:05 
Underlined are the predicted core binding region from P1 to P9 pocket. Citrulline is labelled as X. Mean values 
represent IC50 obtained from three independent experiments. Binding affinity of >250 μM is considered no 
binding (NB) 
 
 
  
Table 2 
 
Data collection and refinement statistics for DRB1*04:01 in complex with self-antigens 
Statistics for the highest-resolution shell are shown in parentheses. r.m.s.d. means root mean square deviation. 
 
 
 
DR401_Fib74Cit, 
PDB code 6BIL 
DR401_Fib72,74Cit 
Fib72, 74Cit, PDB 
code 6BIJ 
DR401_CII1240Cit
, PDB code 6BIN 
DR0401_LL37
_Cit91, PDB 
code 6BIV 
Data collection 
    
Resolution range 32.32–2.40 (2.49–
2.40) 
31.4–2.10 (2.18–2.10) 39.07–2.50 (2.59–
2.50) 
45.08–2.90 
(3.00–2.90) 
Space group C 2 2 21 C 2 2 21 C 2 2 21 C 2 2 21 
Unit cell a, b, c (Å) 67.41, 184.12, 
77.30 
67.01, 177.71, 77.03 67.35, 183.71, 77.19 66.86, 180.30, 
73.67 
Unit cell α, ȕ, Ȗ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Total reflections 38,304 (3691) 54,582 (5354) 33,116 (3281) 20,482 (2016) 
Unique reflections 19,170 (1851) 27,291 (2677) 16,901 (1667) 10,241 (1008) 
Multiplicity 7.1 (6.9) 7.2 (7.3) 5.7 (5.7) 6.9 (7.0) 
Completeness (%) 99.58 (98.09) 99.94 (100.00) 99.88 (100.00) 100.00 (100.00) 
Mean I/σ(I) 11.46 (3.28) 13.21 (2.93) 6.15 (2.13) 7.87 (1.71) 
R-merge 0.0495 (0.2418) 0.04824 (0.2562) 0.1082 (0.3974) 0.06883 
(0.4452) 
CC1/2 0.996 (0.808) 0.997 (0.784) 0.983 (0.49) 0.992 (0.664) 
Wilson B-factor 25.46 21.84 27.37 47.37 
 
    
Refinement 
    
Reflections used in 
refinement 
19,169 (1851) 27,287 (2677) 16,975 (1667) 10,241 (1008) 
Reflections used for R-free 984 (80) 1368 (148) 890 (82) 494 (51) 
R-work 0.1890 (0.2324) 0.1807 (0.2082) 0.2006 (0.2476) 0.2010 (0.2911) 
R-free 0.2431 (0.3120) 0.2386 (0.2646) 0.2380 (0.2868) 0.2484 (0.3151) 
r.m.s.d. (bonds) 0.002 0.009 0.004 0.003 
r.m.s.d. (angles) 0.66 0.92 0.78 0.93 
Ramachandran favored (%) 97.3 97.55 97.58 97.3 
Ramachandran allowed (%) 2.7 2.45 2.42 2.7 
Ramachandran outliers (%) 0 0 0 0 
Average B-factor 26.23 26.75 26.73 44.01 
Macromolecules 25.95 26.15 26.19 43.64 
Ligands 38.54 37.28 54.28 66.62 
Solvent 28.99 31.63 25.19 33.13 
 
  
Table 3 
Data collection and refinement statistics for DRB1*04:04/*04:05 in complex with self-antigens 
Statistics for the highest-resolution shell are shown in parentheses. r.m.s.d. means root mean square deviation. 
 
 
DR0404_LL37_Cit91, 
PDB code 6BIX 
DR0404_His2B, 
PDB code 6BIY 
DR0404_His2Bcit, 
PDB code 6BIZ 
DR0405_Vim424Cit, 
PDB code 6BIR 
Data collection 
    
Resolution range 39.22–2.20 (2.279–2.20) 39.22–2.05 (2.12–
2.05) 
39.09–2.10 (2.18–
2.10) 
39.34–2.3 (2.38–2.30) 
Space group C 2 2 21 C 2 2 21 C 2 2 21 C 2 2 21 
Unit cell a, b, 
c (Å) 
67.34, 183.06, 78.43 67.83, 182.48, 
76.81 
68.19, 182.60, 76.84 67.46, 183.01, 77.08 
Unit cell α, ȕ, Ȗ (°) 90, 90, 90 90, 90, 90 90, 90, 90 90, 90, 90 
Total reflections 50,100 (4930) 59,256 (5892) 56,781 (5590) 42,840 (4064) 
Unique reflections 25,066 (2466) 30,214 (2983) 28,423 (2799) 21,517 (2081) 
Multiplicity 5.5 (5.6) 4.4 (4.5) 7.2 (6.8) 6.8 (6.3) 
Completeness (%) 100.00 (100.00) 99.51 (99.93) 100.00 (100.00) 99.31 (97.61) 
Mean I/σ(I) 8.58 (4.27) 10.20 (2.73) 18.75 (5.06) 9.45 (2.49) 
R-merge 0.03499 (0.1193) 0.05276 (0.2877) 0.03453 (0.191) 0.05655 (0.2767) 
CC1/2 0.997 (0.954) 0.989 (0.739) 0.998 (0.88) 0.995 (0.817) 
Wilson B-factor 19.6 24.92 24.07 25.56 
 
Refinement 
    
Reflections used 
in refinement 
25,064 (2466) 30,210 (2983) 28,422 (2799) 21,511 (2081) 
Reflections used 
for R-free 
1275 (112) 1536 (131) 1416 (155) 1102 (100) 
R-work 0.1692 (0.1749) 0.1825 (0.2410) 0.1856 (0.2404) 0.1858 (0.2347) 
R-free 0.2130 (0.2634) 0.2319 (0.2786) 0.2284 (0.3165) 0.2380 (0.2502) 
r.m.s.d. (bonds) 0.007 0.007 0.008 0.007 
r.m.s.d (angles) 0.98 0.86 0.92 0.96 
Ramachandran 
favored (%) 
98 97.59 98 96.71 
Ramachandran 
allowed (%) 
1.9 2.41 1.9 3.29 
Ramachandran 
outliers (%) 
0 0 0 0 
Average B-factor 22.41 28.64 26.16 25.6 
Macromolecules 21.81 27.95 25.58 25.3 
Ligands 36.68 44.58 40.05 43.44 
Solvent 27.41 33.98 29.92 27.03 
 
 
 
 
  
Fig 1 
 
 
 
Motif analysis of naturally presented peptides 
DRB1*04:05 peptide repertoire analysis reveals amino acids that are more (positive values) or less (negative values) represented in the DRB1*04:05 9-mer 
cores (n = 659) compared with frequencies found in human proteome (A). Heat map depicting position-specific (columns 1–9) amino acid (rows) differences 
in 9-mer cores of the DRB1*04:05 compared with *04:01 and *04:04 on a scale of −100% (decreased in DRB1*04:05) to 100% (increased in DRB1*04:05) 
(B). A marked increase in Asp (21%), and Glu (32%) at P9 was observed in DRB1*04:05 (n = 659) compared with either *04:01 (n = 241) or *04:04 (n = 
265). 
 
 
 
 
 
 
  
Fig 2a 
 
 
Titration curve of self-peptide binding reflected by displacement of reporter fluorescent peptide in HLA-DRB1*04:01 (A), HLA-DRB1*04:04 (B), 
and HLA-DRB1:04:05 (C). 
Each data point represents normalized relative binding (in percentage) from three independent experiments. Mean values are plotted, and error bar showed 
SE Nat, native peptide without citrulline; Cit,citrullinated peptide. Curve fit for each set of peptides for all three allomorphs HLA-DRB1*04:01, HLA-
DRB1*04:04, and HLA-DRB1:04:05 are displayed in Table S2    . 
 
 
  
Fig 2b 
 
 
 
 
 
 
  
Fig 2c 
 
 
 
 
 
  
  
Fig 3 
 
 
 
Polymorphic residues in the peptide-binding cleft of HLA-SE molecules. Polymorphic residues in the P1, P4, and the P9 pocket of HLA-DRB1*04:01, 
DRB1*04:04, DRB1*04:05, and the shared-epitope motif are shown (A). The G86V variation on the DRȕ chain of HLA-DRB1*04:04 may obstruct binding of 
hydrophobic residues such as Tyr in the P1 pocket (B). The P4-Cit forms a conserved hydrogen bond with the Lys-71ȕ/Arg-71ȕ, a polymorphic residue in the 
P4 pocket between HLA-DRB1*04:01 and DRB1*04:04/*04:05 (C). The P9 pocket of HLA-DRB1*04:01 and DRB1*04:04 consists of a Asp-57ȕ that shapes 
the P9 pocket of these two alleles by forming a salt bridge with the conserved Arg-76α (D). The D57S variation on the DRȕ chain of HLA-DRB1*04:05 forms 
extensive hydrogen bonds with P9-Asp in the peptide (E). The P9 pocket of HLA-DRB1*04:05 with a Ser-57ȕ that has a shorter side chain has been shown to 
have a preference for negatively charged residue in the P9 position of peptides.     
 Fig 4 
 
 
 
Crystal structures of HLA-SE in complex with RA-associated antigens. The HLA-DRB1* molecule is represented as a schematic, whereas the RA-
associated peptides are shown as sticks, and the electron density maps of these peptides are shown as 2Fo − Fc maps contoured at 1σ. Both HLA-DRB1*04:01 
(A) and DRB1*04:04 (B) bound to the LL37–91Cit86–98 and interact with the peptide P4-Cit in a highly conserved manner despite Lys-71ȕ/Arg-71ȕ 
polymorphism in the P4 pocket. C, Arg-71ȕ of DRB1*04:05, like the HLA-DRB1*04:01/*04:04, forms a conserved hydrogen bond with the P4-Cit in peptide 
vimentin-424Cit419–431. Crystal structures of HLA-DRB1*04:01 in complex with either fibrinogen-ȕ-74Cit69–81 (D) or fibrinogen-ȕ-72,74Cit69–81 (E), 
the same epitope with additional citrulline in the P2 pocket, showed no register shift upon binding to the DR molecule. The P2-Cit of both fibrinogen-ȕ-
72,74Cit69–81 and F, collagen type II-1240Cit1237–1249 bound to HLA-DRB1*04:01 are projected outward from the peptide-binding groove and are 
accessible by TCRs. The P4-Asp, in collagen type II-1240Cit1237–1249, like the P4-Cit, forms a hydrogen bond with the Lys-71ȕ in HLA-DRB1*04:01. The 
presence of P3-Arg (G) or P3-Cit (H) in the histone2B68–82 peptide does not change the affinity of the peptide for the HLA-DRB1*04:04 and interacts with 
Asn-6βα. The P4-Ile in the histone2B68–82 peptide liberates the Arg-71ȕ in DRB1*04:04 to form a hydrogen bond with P7-Glu and Asp-β8ȕ. I, overlay of the 
eight structures showed no significant conformational changes in the HLA molecules, and the peptide alignment is highly conserved. Citrulline in the P4 
pocket is presented upward in a highly conserved manner.       
